利可特里因受体对抗剂 利可特里因受体对抗剂
1Department of Clinical Pharmacology & Therapeutics, Ninewells Hospital and Medical School, University of Dundee, UK. b.j.lipworth@dundee.uk
Lancet (London, England)
|February 19, 1999
概括
胰岛素受体对抗剂为喘提供了一种新,方便的口服治疗方法,同时作为抗炎和支气管扩展剂. 这些药物还显示出对管理过敏性鼻炎的希望,这种过敏性鼻炎经常与喘同时发生.
科学领域:
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
- 药物开发 药物开发
背景情况:
- 莱科特里因受体对抗剂代表了一类新的抗喘药物.
- 这些药物提供一种独特的抗炎和支气管扩展性质的组合.
- 方便的口服 (每天一次或两次) 是一个关键特征.
研究的目的:
- 为了概述白血抗体的临床药理学.
- 评估已发表的临床试验数据,以评估它们的疗效.
- 确定这些药物在当前喘管理指南中的作用.
主要方法:
- 审查已发表的临床试验数据.
- 对药理学特征进行分析.
- 对各种喘严重程度的疗效的评估.
主要成果:
- 列可素受体对手表现出显著的抗喘活性.
- 在单一治疗和与吸入类固醇联合治疗时观察到有效性.
- 治疗过敏性鼻炎的潜在有效性,通常与喘并发.
结论:
- 利可托里因受体对抗剂是具有有利特征的有效抗喘药物.
- 它们的实用性延伸到同时存在的过敏性鼻炎的管理.
- 这些药物值得在喘管理策略中考虑.
相关概念视频
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...